CSF3 and neutropenia: Analysis of the treatment outcomes according to age groups (non-older patients [age < 65 years] vs. older patients (age ≥ 65 years)) showed that primary G-CSF prophylaxis exerted a significant beneficial effect on OS (14.5 vs. 8.7 months; HR 1.957, 95% CI 1.258–3.042), while reducing the risk of neutropenia (38.9% vs. 60.6%, p = 0.036) and febrile neutropenia (0.0% vs. 16.7%, p = 0.010) and increasing cRDI (85.2% vs. 76.4%, p = 0.007) in non-older patients (Table S1, Figure 2A).